Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.
Lancet Psychiatry April 5, 2017 Ilina Singh, Celia Morgan, Valerie Curran et al. 158 citations
Based on current evidence, off-label ketamine use for severe, treatment-resistant depression does not violate ethical principles, but clinicians and professional bodies must establish guidelines for good practice, register all trial data, and continuously monitor risks. The analysis reviews evidence for ketamine's antidepressant effects and safety profile, concluding with recommendations for oversight bodies to support safe, effective, and ethical treatment.